BioSpecifics Technologies Corp

Type: Company
Name: BioSpecifics Technologies Corp
First reported Sep 19 2014 - Updated Sep 19 2014 - 3 reports

BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference

About BioSpecifics Technologies Corp. BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX® (collagenase ... [Published Industrial Info Financials - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

BioSpecifics Technologies Corp. Announces New MULTICORD and Retreatment Data for XIAFLEX® for Dupuytren's Contracture Presented at American Society for Surgery of the Hand Annual Meeting

LYNBROOK, N.Y., Sept. 18, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ... [Published PR Newswire: General Business - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

BioSpecifics Technologies Corp. Sets New 12-Month High at $33.75 (BSTC)

BioSpecifics Technologies Corp. (NASDAQ:BSTC)’s share price hit a new 52-week high during mid-day trading on Wednesday , AnalystRatings.NET reports. The stock traded as high as $33.75 and last traded at $33.61, with a volume of 60,135 shares. The stock ... [Published American Banking News - Sep 17 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 2 reports

BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences

PR NewswireLYNBROOK, N.Y., Sept. 2, 2014LYNBROOK, N.Y. , Sept. 2, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX ® in the U.S. and ... [Published Reuters - Sep 02 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 2 reports

Update: BioSpecifics Announces Positive XIAFLEX Data For Cellulite

By Andy Batts :BioSpecifics Technologies (NASDAQ: BSTC ) recently announced positive, statistically significant results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum or CCH (known as XIAFLEX in the in the US and ... [Published BioPortfolio - Aug 27 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

BioSpecifics Technologies injects first patient in Phase II lipoma trial

BioSpecifics Technologies Corp., a biopharmaceutical company, has injected the first patient in its placebo-controlled Phase II clinical trial of XIAFLEX, or collagenase clostridium histolyticum, or CCH for the treatment of lipoma. The Company expects ... [Published Individual.com - Aug 25 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

BioSpecifics’ Xiaflex demonstrates efficacy in Phase 2a cellulite study

BioSpecifics Technologies’ collagenase clostridium histolyticum showed promise for smoothing cellulite during a recent randomized, double-blind Phase 2a study in the US. ... [Published PBR - News - Aug 22 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Update: BioSpecifics Technologies Earnings

Summary BioSpecifics reported second quarter 2014 total revenue of $2.7 million, a decrease of 19% year-over-year. Net income came in at $0.6 million or $0.09 per basic share, compared to net income of $1.0 million or $0.16 per basic share in the year-ago ... [Published Seeking Alpha - Aug 15 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the US and XIAPEX in the EU, has injected the first patient in its placebo-controlled ... [Published PharmaAsia - Aug 13 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 1 reports

BioSpecifics Technologies Corp. Reports Second Quarter 2014 Financial Results

LYNBROOK, N.Y., Aug. 11, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ... [Published PR Newswire: Financial Services - Aug 11 2014]
First reported Aug 08 2014 - Updated Aug 09 2014 - 1 reports

BioSpecifics Technologies Corp. Announces Initiation of Phase 2 Clinical Study of CCH for Treatment of Lipoma

LYNBROOK, N.Y., Aug. 8, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ... [Published PR Newswire: Health - Aug 08 2014]
First reported Aug 04 2014 - Updated Aug 05 2014 - 1 reports

BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2014 Financial Results on Monday, August 11, 2014

LYNBROOK, N.Y., Aug. 4, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ... [Published PR Newswire: Health - Aug 04 2014]

Quotes

...advance our pipeline and continue to uncover the vast potential of injectable collagenase," commented Thomas L Wegman, President of BioSpecifics. "Lipomas are common and affect 2% of the total human population. We hope to build upon the positive clinical data reported earlier this year, and to make progress toward potentially offering a nonsurgical therapy to patients with this condition."
"These positive results are very encouraging, particularly because both patients and physicians saw a statistically significant improvement in the appearance of cellulite after CCH treatment" commented Thomas L Wegman
...a statistically significant improvement in the appearance of cellulite after CCH treatment," commented Thomas L Wegman , President of BioSpecifics. "The market for cellulite treatment is large, which makes these data very exciting for the prospective commercial success of CCH in this indication. The results also position CCH as a potential treatment for other aesthetic needs, so we are eager to see continued progress by Auxilium in initiating a subsequent Phase 2b trial of CCH in cellulite in the second quarter of 2015."
...Thomas L Wegman, President of BioSpecifics, said, "This was a momentous quarter of milestones for XIAFLEX both commercially and clinically. We saw significant growth in revenues from XIAFLEX U S sales, most notably in Peyronie's disease. We are particularly pleased to see the number of vials shipped in the second quarter of 2014; 565 in April, 775 in May and then almost double that number in June with 1,412 vials shipped. This was a significant increase over the first quarter shipments of 598 vials."

More Content

All (36) | News (16) | Reports (0) | Blogs (18) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
BioSpecifics Technologies Corp. to Present at t... [Published Industrial Info Financials - Sep 19 2014]
BioSpecifics Technologies : to Present at the 2... [Published 4 Traders - Sep 19 2014]
BioSpecifics Technologies Corp. to Present at t... [Published PR Newswire: General Business - Sep 19 2014]
BioSpecifics Technologies Corp. Announces New M... [Published PR Newswire: General Business - Sep 18 2014]
BioSpecifics Technologies Corp. Sets New 12-Mon... [Published American Banking News - Sep 17 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published Reuters - Sep 02 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published PR Newswire: Health - Sep 02 2014]
Global, China Collagen Industry 2014 to 2019 Fo... [Published FinanzNachrichten.de - Aug 29 2014]
Update: BioSpecifics Announces Positive XIAFLEX... [Published BioPortfolio - Aug 27 2014]
Update: BioSpecifics Announces Positive XIAFLEX... [Published Seeking Alpha - Aug 27 2014]
BioSpecifics Technologies injects first patient... [Published Individual.com - Aug 25 2014]
BioSpecifics’ Xiaflex demonstrates efficacy in ... [Published PBR - News - Aug 22 2014]
BioSpecifics Technologies Corp announces positi... [Published Reuters - Aug 21 2014]
BioSpecifics Technologies Corp. Announces Posit... [Published Bio-Medicine - Aug 21 2014]
BioSpecifics Technologies Corp. Announces Posit... [Published TheStreet.com - Aug 21 2014]
BioSpecifics Technologies Corp. Announces Posit... [Published Stock Nod - Aug 21 2014]
BioSpecifics Technologies Corp. Announces Posit... [Published Reliance Trust - Aug 21 2014]
BioSpecifics Technologies Corp. Announces Posit... [Published PR Newswire: Health - Aug 21 2014]
Update: BioSpecifics Technologies Earnings [Published Seeking Alpha - Aug 15 2014]
BioSpecifics Technologies Corp. Announces Initi... [Published PharmaAsia - Aug 13 2014]
BioSpecifics Technologies Corp. Reports Second ... [Published PR Newswire: Financial Services - Aug 11 2014]
BioSpecifics Technologies Corp. Announces Initi... [Published PR Newswire: Health - Aug 08 2014]
BioSpecifics Technologies Corp. Announces Appoi... [Published Financial Services - Aug 05 2014]
BioSpecifics Technologies Corp. to Host Confere... [Published PR Newswire: Health - Aug 04 2014]
BioSpecifics Technologies Corp (NASDAQ: BSTC) t... [Published GlobeNewswire: Advertising News - Jul 22 2014]
Corporate Updates, Certifications, and Product ... [Published PR Newswire: Financial Services - Jul 02 2014]
BioSpecifics Technologies Corp. to Be Added to ... [Published PR Newswire: Health - Jun 27 2014]
BioSpecifics Technologies Corp. Announces Filin... [Published PR Newswire: Health - Jun 25 2014]
BioSpecifics Announces New Analyses of XIAFLEX ... [Published PR Newswire: Health - May 19 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published PR Newswire: General Business - May 12 2014]
1 2
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BioSpecifics Technologies Corp. to Present at t... [Published PR Newswire: General Business - Sep 19 2014]
LYNBROOK, N.Y., Sept. 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that ...
BioSpecifics Technologies Corp. Announces New M... [Published PR Newswire: General Business - Sep 18 2014]
LYNBROOK, N.Y., Sept. 18, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ...
BioSpecifics Technologies Corp. Announces Prese... [Published PR Newswire: Health - Sep 02 2014]
LYNBROOK, N.Y., Sept. 2, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that ...
BioSpecifics’ Xiaflex demonstrates efficacy in ... [Published PBR - News - Aug 22 2014]
BioSpecifics Technologies’ collagenase clostridium histolyticum showed promise for smoothing cellulite during a recent randomized, double-blind Phase 2a study in the US. ...
BioSpecifics Technologies Corp. Announces Posit... [Published PR Newswire: Health - Aug 21 2014]
LYNBROOK, N.Y., Aug. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. ...
1 2 3 4

Press Releases

sort by: Date | Relevance
BioSpecifics Technologies Corp. Announces Appoi... [Published Financial Services - Aug 05 2014]
BioSpecifics Technologies Corp (NASDAQ: BSTC) t... [Published GlobeNewswire: Advertising News - Jul 22 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.